AKESO Shares Climb Over 4% Again Following Clinical Trial Approval for First Trispecific Antibody
Stock News
Mar 16
AKESO (09926) saw its share price rise more than 4% again. At the time of writing, the stock was up 4.26% to HK$114.9, with a turnover of HK$529 million. The increase follows recent news that the company's novel trispecific antibody drug, AK150, has received implicit approval from the National Medical Products Administration (NMPA) for clinical trials. AK150 is intended for the treatment of advanced malignant solid tumors. Developed using AKESO's AI-driven drug discovery platform and Tetrabody multispecific antibody technology, AK150 is a first-in-class ILT2/ILT4/CSF1R trispecific antibody and represents the company's first trispecific antibody candidate to enter the clinical stage.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.